Sign in
CompletedPhase 3

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Key facts

Who runs it
argenx
Where
Columbus, Iowa City, Ocala, and Washington D.C., United StatesSee the 4 sitesAlso in 17 other countries, 68 sites
Status
Completed
Phase
Phase 3
People taking part
101 people enrolled
Started
2 Jun 2020
Ended
11 Mar 2026
Type of study
Interventional
Treatments tested
  • efgartigimod
Record updated
16 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits)
  • Patients enrolled in the ARGX-113-1801 trial who completed the 24-weeks trial period
  • Women of childbearing potential must have a negative urine pregnancy test at baseline before trial medication (infusion) can be administered
  • Women of childbearing potential should use a highly effective or acceptable method of contraception during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month (as listed in the protocol)
  • Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits)
  • Patient has completed a 52-week treatment period

Who cannot take part

  • Introduction or continuation of non-permitted medications during the ARGX-113-1801 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins or live/live-attenuated vaccines)
  • Use of any other investigational drug or participation in any other investigational trial
  • Patients with known medical history of hypersensitivity to any of the ingredients of efgartigimod
  • Pregnant or lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing

Where in United States

Also in 17 other countries, 68 sites

  • Columbus, OhioHospital not named in the registry
  • Iowa City, IowaHospital not named in the registry
  • Ocala, FloridaHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

About the trial

What the trial wants to find out

This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.

The group in the trial

  • efgartigimodTreatment being tested

    patients receiving efgartigimod

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.
Record updated
16 March 2026